Search

Cell-Free Vascular Grafts and Graft Materials for Cellular Recruitment

USPTO published patent application US20260097149A1 for cell-free vascular graft materials incorporating bispecific binding partners with luminal and cellular binding domains for cellular recruitment. The application, filed June 26, 2023 under Application No. 18880781, covers fusion peptides with heparin and monocyte binding domains, methods of making the grafts, and methods of use including A-TEV technology.

Method for Treating Neurodegenerative Diseases with Polymer-Flavonoid Conjugates

The USPTO published patent application US20260097130A1 for a method of treating neurodegenerative diseases using polymer-flavonoid conjugates. Inventors Chun-Ting Cheng, Kuo-Liang Hou, and Pauline Ying Lau claim compositions that enable therapeutic materials to cross the blood-brain barrier. The application covers treatment of Alzheimer's disease, Parkinson's disease, Lewy body dementia, and Huntington's disease using the disclosed nanocomplex formulations.

Silver Nanoparticle Treatment for Carious Lesions, 3-5 Weeks

The USPTO published patent application US20260096959A1 filed by R.M CREIGHTON DENTAL PTY LTD for a method of treating carious lesions using silver nanoparticles. The treatment involves applying a first dental solution containing a silver salt followed by a second dental solution containing a reducing agent within less than 10 minutes. The lesion consolidates over 3-5 weeks to form a matte black crust containing nanoparticles. Invented by Graham G. Craig.

Anhydrous Powder Hair Lightening Suspension

USPTO published patent application US20260096960A1 by inventor David Erlingheuser for an anhydrous powder hair lightening suspension composition on April 9, 2026. The composition comprises 5-60% non-volatile oil, 3-30% petrolatum, 0.05-5% fumed silica, 1-70% persulfate salt, and 0% microplastics. This publication establishes a priority date and provides public notice of the pending patent claims.

Circular DNA Purification Using Nanoclays

USPTO published patent application US20260098252A1 by Texas State University (filed October 3, 2025) disclosing a method of purifying circular DNA from samples using nanoclays that preferentially adsorb contaminants including non-circular DNA, RNA, proteins, and endotoxins while leaving circular DNA unbound. The elution-free method separates nanoclay-contaminant complexes from the enriched circular DNA fraction. The invention also covers compositions and systems for such purification and methods of refining nanoclays for the purification process.

CO2 Conversion to C2+ Chemicals via Electrochemical and Microbial Process

USPTO published patent application US20260098282A1 disclosing a method for converting carbon dioxide to higher value C2+ chemicals using an electrochemical cell with a carbon dioxide reducing catalyst combined with microbial conversion. The application was filed on September 23, 2023, by inventors Peng Zhang, Kainan Chen, Joshua Shuhua Yuan, and Susie Y. Dai. The publication makes the application publicly available but does not constitute a granted patent.

In Vitro Bioproduction of Polyhydroxyalkanoate Monomers

USPTO published patent application US20260098283A1 by inventor Stephen Quirk for an enzymatic process to produce homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acids. The process enables specific, controlled production of PHA materials through in vitro enzyme contact with long-chain fatty acid precursors.

Lysis Vessel with Dual Membranes and Non-Magnetic Beads for On-Board Cell Lysis

USPTO published patent application US20260098253A1 assigned to Gen-Probe Incorporated. The application covers a lysis vessel for performing cell lysis that includes a laterally extending member and sleeve with dual porous membranes, non-magnetic beads, and at least one magnetic element contained within a lysis chamber. Filing date was December 11, 2025, under application number 19416385.

Nucleic Acid Extraction Methods, Waters Corp, 9th Apr

Nucleic Acid Extraction Methods, Waters Corp, 9th Apr

BEST1 Vectors for Retinal Dystrophy Treatment

The USPTO published patent application US20260098277A1 covering BEST1-targeted expression constructs, nucleic acid vectors, and pharmaceutical compositions for treating BEST1-associated retinal dystrophies including autosomal dominant bestrophinopathies. The application includes BEST1-targeted shRNAs, BEST1 coding sequences, promoters, and regulatory elements designed to improve functional BEST1 expression in subjects with BEST1 mutations. This published application represents an early-stage intellectual property filing with no granted rights or compliance obligations established.